A systematic pipeline of protein structure selection for computer-aided drug discovery: A case study on T790M/L858R mutant EGFR structures

被引:1
|
作者
Das, Agneesh Pratim [1 ,2 ]
Nandekar, Prajwal [3 ]
Mathur, Puniti [2 ]
Agarwal, Subhash M. [1 ,4 ]
机构
[1] ICMR Natl Inst Canc Prevent & Res, Bioinformat Div, Noida, Uttar Pradesh, India
[2] Amity Univ Uttar Pradesh, Amity Inst Biotechnol, Noida, Uttar Pradesh, India
[3] Schrodinger India Pvt Ltd, Bengaluru, Karnataka, India
[4] ICMR Natl Inst Canc Prevent & Res, Bioinformat Div, I-7,Sect 39, Noida 201301, Uttar Pradesh, India
关键词
binding pose metadynamics; cross docking; drug discovery; EGFR; kinase; structure selection; virtual screening; NONCOVALENT INHIBITORS; RECEPTOR; DOCKING; RESISTANCE; BINDING;
D O I
10.1002/pro.4740
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Virtual screening (VS) is a routine method to evaluate chemical libraries for lead identification. Therefore, the selection of appropriate protein structures for VS is an essential prerequisite to identify true actives during docking. But the presence of several crystal structures of the same protein makes it difficult to select one or few structures rationally for screening. Therefore, a computational prioritization protocol has been developed for shortlisting crystal structures that identify true active molecules with better efficiency. As identification of small-molecule inhibitors is an important clinical requirement for the T790M/L858R (TMLR) EGFR mutant, it has been selected as a case study. The approach involves cross-docking of 21 co-crystal ligands with all the structures of the same protein to select structures that dock non-native ligands with lower RMSD. The cross docking performance was then correlated with ligand similarity and binding-site conformational similarity. Eventually, structures were shortlisted by integrating cross-docking performance, and ligand and binding-site similarity. Thereafter, binding pose metadynamics was employed to identify structures having stable co-crystal ligands in their respective binding pockets. Finally, different enrichment metrics like BEDROC, RIE, AUAC, and EF1% were evaluated leading to the identification of five TMLR structures (5HCX, 5CAN, 5CAP, 5CAS, and 5CAO). These structures docked a number of non-native ligands with low RMSD, contain structurally dissimilar ligands, have conformationally dissimilar binding sites, harbor stable co-crystal ligands, and also identify true actives early. The present approach can be implemented for shortlisting protein targets of any other important therapeutic kinases.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Discovery and optimization of covalent EGFR T790M/L858R mutant inhibitors
    Hoogenboom, Niels
    Demont, Dennis
    de Zwart, Edwin
    Verkaik, Saskia
    Emmelot, Maaike
    van de Kar, Bas
    Kaptein, Allard
    Barf, Tjeerd
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 52
  • [2] QSAR of clinically important EGFR mutant L858R/T790M pyridinylimidazole inhibitors
    Fatima, Shehnaz
    Pal, Divyani
    Agarwal, Subhash Mohan
    CHEMICAL BIOLOGY & DRUG DESIGN, 2019, 94 (01) : 1306 - 1315
  • [3] Structural insight into the binding mechanism of ATP to EGFR and L858R, and T790M and L858R/T790 mutants
    Saldana-Rivera, Lucia
    Bello, Martiniano
    Mendez-Luna, David
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2019, 37 (17) : 4671 - 4684
  • [4] Discovery of novel selective inhibitors for EGFR-T790M/L858R
    Bai, Fang
    Liu, Hongyan
    Tong, Linjiang
    Zhou, Wei
    Liu, Li
    Zhao, Zhenjiang
    Liu, Xiaofeng
    Jiang, Hualiang
    Wang, Xicheng
    Xie, Hua
    Li, Honglin
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (03) : 1365 - 1370
  • [5] Binding mechanism of kinase inhibitors to EGFR and T790M, L858R and L858R/T790M mutants through structural and energetic analysis
    Bello, Martiniano
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2018, 118 : 1948 - 1962
  • [6] Furopyridine Derivatives as Potent Inhibitors of the Wild Type, L858R/T790M, and L858R/T790M/C797S EGFR
    Todsaporn, Duangjai
    Zubenko, Alexander
    Kartsev, Victor G.
    Mahalapbutr, Panupong
    Geronikaki, Athina
    Sirakanyan, Samvel N.
    Divaeva, Lyudmila N.
    Chekrisheva, Victoria
    Yildiz, Ilkay
    Choowongkomon, Kiattawee
    Rungrotmongkol, Thanyada
    JOURNAL OF PHYSICAL CHEMISTRY B, 2024, 128 (50) : 12389 - 12402
  • [7] L858R/T790M Discovery of highly potent and selective CRBN-recruiting EGFRL858R/T790M degraders in vivo
    Zhang, Wenjuan
    Li, Pengyun
    Sun, Shiyang
    Jia, Changkai
    Yang, Ning
    Zhuang, Xiaomei
    Zheng, Zhibing
    Li, Song
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 238
  • [8] Identification of potential edible spices as EGFR and EGFR mutant T790M/L858R inhibitors by structure-based virtual screening and molecular dynamics
    Ansari, Iqrar Ahmad
    Debnath, Bimal
    Kar, Saikat
    Patel, Harun M.
    Debnath, Sudhan
    Zaki, Magdi E. A.
    Pal, Pinaki
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024, 42 (05) : 2464 - 2481
  • [9] Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR
    Foschi, Francesca
    Tinivella, Annachiara
    Crippa, Valentina
    Pinzi, Luca
    Mologni, Luca
    Passarella, Daniele
    Rastelli, Giulio
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2023, 38 (01) : 239 - 245
  • [10] Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant
    Qin, Xuemei
    Li, Zhipeng
    Yang, Leifu
    Liu, Peng
    Hu, Liming
    Zeng, Chengchu
    Pan, Zhiyong
    BIOORGANIC & MEDICINAL CHEMISTRY, 2016, 24 (13) : 2871 - 2881